MAZE THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MAZE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.70M.
- MAZE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $4.08M, a 3137.30% increase year-over-year.
- MAZE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $2.01M, a 720.00% increase year-over-year.
- MAZE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $126.00K, a 65.48% decline year-over-year.
- MAZE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $5.56M, a 626.93% increase from fiscal 2024.
- MAZE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $765.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.70M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $4.08M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $5.56M 10-K · filed 2026-03-25 | |
| 2025-09-30 | $2.01M 10-Q · filed 2025-11-06 | |
| 2025-03-31 | $126.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $765.00K 10-K · filed 2026-03-25 | |
| 2024-09-30 | $245.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $79.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $365.00K 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |